Listing of Claims:

Claims 1-19 (Canceled).

20. (Currently amended) A copolymer-1 composition comprising a mixture of polypeptides composed of glutamic acid, lysine, alanine and tyrosine, wherein the mixture has an average molecular weight of about 4 to about 9 kilodaltons, ~~and~~ wherein the mixture of polypeptides is non-uniform with respect to molecular weight and ~~constitution~~ sequence, and wherein the composition is suitable for treating multiple sclerosis.

21. (Previously presented) The composition of claim 20, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.

22. (Currently amended) The composition of claim 20, wherein less than 5% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight of over 40 kilodaltons.

23. (Previously presented) The composition of claim 22, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.

24. (Previously presented) The composition of claim 23, wherein the mixture has an average molecular weight of 6.25 to 8.4 kilodaltons.

25. (Previously presented) The composition of claim 20, wherein the mixture has an average molecular weight of about 4 to about 8.6 kilodaltons.

26. (Previously presented) The composition of claim 20, wherein the mixture has an average molecular weight of about 5 to about 9 kilodaltons.

27. (Currently amended) The composition of claim 20, wherein less than 2.5% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight of over 40 kilodaltons.

28. (Previously presented) The composition of claim 27, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.

29. (Previously presented) The composition of claim 28, wherein the mixture has an average molecular weight of 6.25 to 8.4 kilodaltons.

30. (Previously presented) The composition of claim 20, wherein the mixture has a molecular weight distribution substantially as depicted in the curves of Figure 1 or Figure 2 in which the average molecular weight is about 7.7 kDa.

31. (Canceled)

32. (Canceled)

33. (New) A pharmaceutical composition comprising:

a dose therapeutically effective to treat multiple sclerosis of a copolymer-1 composition, wherein the copolymer-1 composition comprises a mixture of polypeptides composed of glutamic acid, lysine, alanine and tyrosine, wherein the mixture has an average molecular weight of about 4 to about 9 kilodaltons, wherein the mixture of polypeptides is non-uniform with respect to molecular weight and sequence; and

a pharmaceutically acceptable excipient.

34. (New) The pharmaceutical composition of claim 33, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.

35. (New) The pharmaceutical composition of claim 33, wherein less than 5% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight of over 40 kilodaltons.

36. (New) The pharmaceutical composition of claim 35, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.

37. (New) The pharmaceutical composition of claim 36, wherein the mixture has an average molecular weight of 6.25 to 8.4 kilodaltons.

38. (New) The pharmaceutical composition of claim 33, wherein the mixture has an average molecular weight of about 4 to about 8.6 kilodaltons.

39. (New) The pharmaceutical composition of claim 33, wherein the mixture has an average molecular weight of about 5 to about 9 kilodaltons.

40. (New) The pharmaceutical composition of claim 33, wherein less than 2.5% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight of over 40 kilodaltons.

41. (New) The pharmaceutical composition of claim 40, wherein over 75% of the polypeptides of the mixture, on a molar fraction basis, have a molecular weight in a range of about 2 kilodaltons to about 20 kilodaltons.

42. (New) The pharmaceutical composition of claim 41, wherein the mixture has an average molecular weight of 6.25 to 8.4 kilodaltons.

43. (New) The pharmaceutical composition of claim 33, wherein the mixture has a molecular weight distribution substantially as depicted in the curves of Figure 1 or Figure 2 in which the average molecular weight is about 7.7 kDa.

44. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 33.

45. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 34.

46. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 35.

47. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 36.

48. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 37.

49. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 38.

50. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 39.

51. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 40.

52. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 41.

53. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 42.

54. (New) A method for treating a patient suffering from multiple sclerosis comprising administering to a patient in need thereof the pharmaceutical composition of claim 43.